James Foran, MD
Hematology & Oncology · Jacksonville, FLNPI 1992749139
Payments from drug & device makers
Across 419 payments — averaging $10,864 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2M
- Novartis$462K
- AbbVie$449K
- Bristol Myers Squibb$429K
- Stemline Therapeutics Inc.$264K
- Boehringer Ingelheim$147K
- plus $783K from 24 others
Across 2 payments — averaging $286.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Servier Bioinnovation$574
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 56 | $2,017,958 |
| Novartis | 28 | $461,954 |
| AbbVie | 50 | $448,830 |
| Bristol Myers Squibb | 9 | $428,582 |
| Stemline Therapeutics Inc. | 21 | $263,941 |
| Boehringer Ingelheim | 5 | $147,181 |
| Servier Bioinnovation | 10 | $137,119 |
| Boehringer Ingelheim International GmbH | 19 | $126,362 |
| Servier Pharmaceuticals LLC | 17 | $125,278 |
| Pfizer | 14 | $111,938 |
| Otsuka Pharmaceutical Co., Ltd. | 5 | $87,153 |
| Astellas Pharma Global Development | 16 | $57,721 |
| Taiho Oncology, Inc. | 80 | $37,126 |
| Agios Pharmaceuticals, Inc. | 12 | $29,169 |
| Syndax Pharmaceuticals, Inc. | 15 | $11,640 |
| Macrogenics, Inc. | 4 | $9,494 |
| Amgen | 2 | $7,124 |
| E.r. Squibb & Sons, L.L.C. | 3 | $5,783 |
| Daiichi Sankyo Inc. | 3 | $5,250 |
| Beigene USA, Inc. | 7 | $4,637 |
| CTI Biopharma Corp. | 3 | $4,536 |
| Jazz Pharmaceuticals Inc. | 11 | $4,383 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 13 | $3,722 |
| Rigel Pharmaceuticals, Inc. | 7 | $3,657 |
| Sanofi | 1 | $3,125 |
| Geron Corporation | 3 | $3,047 |
| AstraZeneca | 2 | $2,241 |
| Genentech USA, Inc. | 1 | $1,925 |
| Acceleron Pharma, Inc. | 1 | $845 |
| Gilead | 1 | $116 |
How this compares
$4,551,837 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Jacksonville
- Steven AttiaJacksonville$13.9M
- Sikander AilawadhiJacksonville$9.8M
- Vamsidhar VelchetiJacksonville$8.2M
- Asher Chanan KhanJacksonville$5.8M
- Yanyan LouJacksonville$4.8M
- Arnab BasuJacksonville$4.6M
- Jennifer CrozierJacksonville$3.5M
- Ayed AyedJacksonville$3.4M
- Saranya ChumsriJacksonville$3.3M
- Gerardo Colon-OteroJacksonville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.